Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses (2022 - 2025)

Entrada Therapeutics has reported Change in Accured Expenses over the past 4 years, most recently at $2.2 million for Q4 2025.

  • Quarterly results put Change in Accured Expenses at $2.2 million for Q4 2025, up 605.88% from a year ago — trailing twelve months through Dec 2025 was $4.7 million (up 177.63% YoY), and the annual figure for FY2025 was $4.7 million, up 177.63%.
  • Change in Accured Expenses for Q4 2025 was $2.2 million at Entrada Therapeutics, down from $3.7 million in the prior quarter.
  • Over the last five years, Change in Accured Expenses for TRDA hit a ceiling of $6.9 million in Q3 2022 and a floor of -$5.5 million in Q1 2025.
  • Median Change in Accured Expenses over the past 4 years was $1.8 million (2023), compared with a mean of $751500.0.
  • Biggest five-year swings in Change in Accured Expenses: tumbled 795.59% in 2023 and later soared 605.88% in 2025.
  • Entrada Therapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then skyrocketed by 145.03% to $2.0 million in 2023, then plummeted by 121.74% to -$425000.0 in 2024, then soared by 605.88% to $2.2 million in 2025.
  • The last three reported values for Change in Accured Expenses were $2.2 million (Q4 2025), $3.7 million (Q3 2025), and $4.3 million (Q2 2025) per Business Quant data.